Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Drone-QR is a marketed fixed-dose combination of astaxanthin and reduced coenzyme Q10 (ubiquinol) developed by Gynogen. It is formulated as oral softgel capsules containing 16 mg of astaxanthin (10%) and 200 mg of ubiquinol. Drone-QR is primarily indicated for the management of male and female infertility, where it helps improve sperm count, motility, and morphology, as well as enhancing ovarian response, oocyte production, and ovum quality. The combination works synergistically to reduce cellular oxidative stress and support mitochondrial energy (ATP) production, thereby promoting overall reproductive, cardiovascular, and skin health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Drone-QR.